(A joint stock company incorporated in the People's Republic of China with limited liability) Stock Code: 1513
2022 INTERIM REPORT
* For identification purpose only
CONTENTS | FINANCIAL HIGHLIGHTS | 3 |
SECTION I | ||
IMPORTANT NOTICE AND DEFINITIONS | 5 | |
SECTION II | ||
COMPANY PROFILE AND MAJOR FINANCIAL INDICATORS | 11 | |
SECTION III | ||
MANAGEMENT DISCUSSION AND ANALYSIS | 16 | |
SECTION IV | ||
CORPORATE GOVERNANCE | 86 | |
SECTION V | ||
MAJOR EVENTS | 91 | |
SECTION VI | ||
ENVIRONMENTAL AND SOCIAL RESPONSIBILITY | 107 | |
SECTION VII | ||
CHANGES IN EQUITY AND SHAREHOLDERS | 131 | |
SECTION VIII | ||
INFORMATION ON PREFERRED SHARES | 143 | |
SECTION IX | ||
INFORMATION ON BONDS | 144 | |
SECTION X | ||
FINANCIAL REPORT | 145 |
LIST OF DOCUMENTS AVAILABLE FOR INSPECTION
- Full text of the 2022 Interim Report of the Company signed by the legal representative.
- The unaudited financial report for the six months ended 30 June 2022 of the Company prepared in accordance with the China Accounting Standards for Business Enterprises, which has been signed and sealed by the person-in-charge of the Company, the person-in-charge of the Company's accounting work and the person-in-charge of the accounting department (the head of the accounting department).
- The original copies of all documents and announcements of the Company which have been disclosed to the public on the website designated by the CSRC during the Reporting Period.
(IV) | The English and Chinese versions of the 2022 Interim Report of the Company published on the website of the Hong |
Kong Exchanges and Clearing Limited. |
2 | Livzon Pharmaceutical Group Inc. Interim Report 2022 |
FINANCIAL HIGHLIGHTS
Major financial indicators (RMB in millions) | |||
1.08% | Same Period | ||
Last Year | |||
6,235.53 6,302.57 | Reporting Period | ||
-4.23% | 13.73% | 111.34% | -3.54% | ||||||||
1,426.39 | 1,371.17 | ||||||||||
1,062.48 | 1,017.55 | 920.07 | 1,046.42 | 1,322.57 | |||||||
674.91 | |||||||||||
Operating income | Net profit attributable | Net profit after | Net cash flow from | Total profit | |||||||
to shareholders of | extraordinary gains or | operating activities | |||||||||
the Company | losses attributable to | ||||||||||
shareholders of | |||||||||||
the Company |
Basic earnings per share (RMB/share) | Diluted earnings per share (RMB/share) |
-4.39%
1.14 | 1.09 |
Same Period | ||
Last Year | ||
-4.39% | Reporting Period | |
1.14 | 1.09 |
Composition of principal businesses (RMB in millions)
5.55%
346.04
7.86%
490.62
27.72%
1,729.34
1.45%
90.52
3.12%
194.65
Income of Principal
Businesses
Total
6,239.73
Chemical drug preparations
Gastroenterology | ||
Gonadotropic hormones | ||
28.54% | Psychiatry | |
Anti-infection | ||
1,780.51 | ||
Other chemical drug | ||
preparations | ||
APIs and intermediates | ||
Traditional Chinese | ||
21.54% | medicine preparations | |
1,344.05 | Diagnostic reagents | |
and equipment |
4.23%
264.00
Livzon Pharmaceutical Group Inc. Interim Report 2022 | 3 |
FINANCIAL HIGHLIGHTS
Unit: RMB in millions | |
Chemical drug preparations | Unit: RMB in millions |
-8.16%
1,938.70
1,780.51
6.82%
1,344.05
1,258.19
36.26% | -0.25% | |||||||||
264.00 | ||||||||||
193.75 | 195.13 | 194.65 | ||||||||
Previous Period Reporting Period | Previous Period Reporting Period | Previous Period Reporting Period | Previous Period Reporting Period | |||||||
Gastroenterology | Gonadotropic | Psychiatry | Anti-infection | |||||||
hormones | ||||||||||
APIs and intermediates | Traditional Chinese | Diagnostic reagents and | ||||||||
medicine preparations | equipment | |||||||||
18.26%1,729.34
1,462.31
610.26
-19.60%
-11.43%
490.62
390.68
346.04
Previous Period | Reporting Period | Previous Period | Reporting Period | Previous Period | Reporting Period |
4 | Livzon Pharmaceutical Group Inc. Interim Report 2022 |
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Livzon Pharmaceutical Group Inc. published this content on 10 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 August 2022 11:13:05 UTC.